News

The Charcot-Marie-Tooth Association July 17 hailed the news that global healthcare giant Novartis is acquiring DTx Pharma and its CMT1A therapy DTx-1252 as a significant step forward for the acceleration of novel CMT treatments capable of reaching the peripheral nervous ...

Professor Robert Burgess and his team at The Jackson Laboratory in Bar Harbor, Maine, is developing both drug treatments and gene therapies for CMT2D with excellent results in mouse models of the disease. CMT2D is caused by mutations in a gene ...

The Charcot-Marie-Tooth Association (CMTA) announced the results of a review of its long-running list of medications known or suspected of being toxic to the peripheral nervous system. With two exceptions for anticancer drugs, the reviewers concluded that the vast majority ...

Scientists at the UCL Queen Square Institute of Neurology in London have identified a new potential therapeutic strategy for CMT type 2D (CMT2D) that may be more broadly effective for treating neuropathy. CMT2D is caused by mutations in the GARS1 ...

CMT is a genetic disease caused by distinct changes in the DNA of a patient and these are typically transmitted in families. Although over 100 different genes, each causing a CMT subtype, have already been identified, more than 50% of ...